Relationship of the polymorphism -308A>G of the TNFα gene with the clinical evolution of patients with COVID-19
Keywords:
SARS-CoV-2, COVID-19, TNFα-308A>G polymorphismAbstract
Introduction: Since the beginning of coronavirus disease 2019 in Cuba, differences have been observed in the disease that could be partially explained by the TNFα-308A>G polymorphism.
Objective: To determine the degree to which the presence of the -308A>G polymorphism of the TNFα gene influences the clinical evolution of individuals infected with SARS-CoV-2.
Method: A cross-sectional analytical study was carried out at the National Center for Medical Genetics, from June 2020 to June 2021.
Results: Patients with the presence of the TNFα-308A>G polymorphism have almost two times more risk of presenting pain when breathing, 1.6 times more risk of presenting sore throat.
Conclusions: The presence of the -308.A allele of the TNFα gene increases the risk of presenting symptoms of COVID-19 in Cuban patients infected with the SARS-CoV-2 virus, although there is no evidence of an increased risk of developing severe forms of the disease. disease in individuals carrying the -308.A allele compared to subjects who do not carry it. The TNFα.-308A allele increases the risk of developing symptoms and presenting severe forms of COVID-19 in the eastern region of the country.
Downloads
References
1- Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol [Internet]. 2020 Jun 1 [cited 2020 Jul 2];20(6):355–62. Available from: https://www.nature.com/articles/s41577-020-0331-4
2- Gil del Valle L, Rabeiro Martinez CL, Bermúdez Alfonso Y, Hernández Glez-Abreu MC. El reposicionamiento terapeútico en el enfrentamiento a la pandemia de infección por SARS-COV 2. Boletín Epidemiológico del IPK [Internet]. 2020 Jul 7 [citado 10 Jul 2020];30(25):195–9. Disponible en: https://files.sld.cu/ipk/2020/07/07/boletin-epidemiologico-del-ipk-no-25-2020/
3- Dirección Nacional de Epidemiología (MINSAP). Boletín epidemiológico semanal. Boletín Epidemiológico del IPK [Internet]. 2020[citado 10 Jul 2020];30(14): 105. Disponible en: https://files.sld.cu/ipk/files/2020/04/Bol-14w-20-.pdf
4- Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis. Diabetes, Obes Metab [Internet]. 2020 Jun 23 [cited 2020 Jul 10];2020. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.14124
5- Chen XY, Yan BX, Man XY. TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis. Ther Adv Respir Dis [Internet]. 2020 [cited 2020 Jul 2];14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243041/
6- Churchill BM. PP. CR. & IJK. TNF-α, TNF Receptors and Their Complex Implications in Therapy. Asian J Immunol [Internet]. 2020 [cited 2020 Jul 10];4(1):36–50. Available from: http://www.journalaji.com/index.php/AJI/article/view/30127
7- Wilson A, Symons J, McDowell T, McDevitt H, Duff. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA [Internet]. 1997 [cited 2020 Jul 10]; 94(7): 3195–3199. Available from: https://www.pnas.org/content/pnas/94/7/3195.full.pdf
8- Abraham L, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. Journal of leukocyte biology [Internet].1999[cited 2020 Jul 10];66(4): 562–566.Available from: http://dx.doi.org/10.1002/jlb.66.4.562
9- Sotomayor F, Marcheco B, Rodríguez K, Esperón A, Flores RM, Menocal A, et al. Relation of polymorphisms vascular endothelial growth factor (+ 405G> C) and tumor necrosis factor alpha (− 308A> G) with the embryo implantation in Cubans patient. Rev. med. Hosp. Gen. Méx. [Internet].2020 [cited 2020 Jul 10]; 83(2): 52-58. Available from: https://www.scielo.org.mx/pdf/rmhgm/v83n2/0185-1063-rmhgm-83-2-52.pdf
10- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020 Mar 13 [cited 2020 Jul 14];3. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184
11- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020 Mar 28 [cited 2020 Jul 13];395(10229):1054–62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270627/
12- Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr [Internet]. 2020 Jul 1 [cited 2020 Jul 14];14(4):513–7. Available from: https://www.sciencedirect.com/science/article/pii/S1871402120301144?via%3Dihub
13- Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 Jul 1 [cited 2020 Jul 14];14(4):535–45. Available from: https://www.sciencedirect.com/science/article/pii/S1871402120301090?via%3Dihub
14- Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertens y Riesgo Vasc [Internet]. 2020 Jun 18 [citado 20 Jul 2020];30(20). Disponible en: https://dx.doi.org/10.1016%2Fj.hipert.2020.06.003
15- Hosseinzadeh R, Goharrizi MASB, Bahardoust M, Alvanegh AG, Ataee MR, Bagheri M, et al. Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)? Clin Hypertens [Internet]. 2021 Dec 15 [cited 2021 Feb 2];27(1):3. Available from: https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-021-00161-7
16- Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis [Internet]. 2016 [cited 2021 Mar 7]; 49:129–33. Available from: https://doi.org/10.1016/j.ijid.2016.06.015
17- Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, et al. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 Sep 1 [cited 2021 Aug 1];14(5):1149–51. Available from: https://doi.org/10.1016/j.dsx.2020.06.060
18- Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain Behav Immun [Internet]. 2020 Jul 1 [cited 2021 Aug 1]; 87:184–7. Available from: https://doi.org/10.1016/j.bbi.2020.05.059
19- Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and Morbidity Associated with Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open [Internet]. 2020 Jun 1 [cited 2021 Aug 1];3(6):e2012270. Available from: https://dx.doi.org/10.1001%2Fjamanetworkopen.2020.12270
20- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020 Mar 28 [cited 2021 Mar 7];395(10229):1033–4. Available from: https://doi.org/10.1016/s0140-6736(20)30628-0
21- Angioni R, Sánchez-Rodríguez R, Munari F, Bertoldi N, Arcidiacono D, Cavinato S, et al. Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death Dis [Internet]. 2020 Nov 1 [cited 2021 Mar 8];11(11). Available from: https://doi.org/10.1038/s41419-020-03151-z
22- Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med [Internet]. 2020 Oct 1 [cited 2021 Mar 7];26(10):1636–43. Available from: https://doi.org/10.1038/s41591-020-1051-9
23- Wilson AG, Symons JA, Mcdowell TL, Mcdevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A [Internet]. 1997 Apr 1 [cited 2021 Mar 7];94(7):3195–9. Available from: https://doi.org/10.1073/pnas.94.7.3195
24- Włodarczyk M, Ciebiera M, Nowicka G. TNF-α G-308A genetic variants, serum CRP-hs concentration and DNA damage in obese women. Mol Biol Rep [Internet]. 2020 Feb 1 [cited 2020 Aug 22];47(2):855–66. Available from: https://dx.doi.org/10.1007%2Fs11033-019-04764-0
25- Stefferl A, Hopkins SJ, Rothwell NJ, Luheshi GN. The role of TNF-α in fever: opposing actions of human and murine TNF-α and interactions with IL-β in the rat. Br J Pharmacol [Internet]. 1996 Aug 1 [cited 2021 Mar 1];118(8):1919–24. Available from: http://doi.wiley.com/10.1111/j.1476-5381.1996.tb15625.x
26- Burdon D, Tiedje T, Pfeffer K, Vollmer E, Zabel P. The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit Care Med [Internet]. 2000 [cited 2021 Mar 1];28(6):1962–7. Available from: https://journals.lww.com/ccmjournal/Abstract/2000/06000/The_role_of_tumor_necrosis_factor_in_the.45.aspx
27- Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J Clin Med [Internet]. 2020 Jun 5 [cited 2021 Mar 7];9(6):1753. Available from: https://dx.doi.org/10.3390%2Fjcm9061753
28- Saleh A, Sultan A, Elashry M a., Farag A, Mortada MI, Ghannam MA, et al. Association of TNF-α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients. Immunol Invest [Internet]. 2020 [cited 2021 Mar 1];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711738/
29- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S mok, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis [Internet]. 2020 May 1 [cited 2021 Mar 1];94:154–5. Available from: https://doi.org/10.1016/j.ijid.2020.03.020
30- Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect [Internet]. 2020 Jun 1 [cited 2021 Mar 1];80(6):656–65. Available from: https://dx.doi.org/10.1016%2Fj.jinf.2020.03.041
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.
